trending Market Intelligence /marketintelligence/en/news-insights/trending/rxG65_gnj4-b1Dpn7w-VFA2 content esgSubNav
In This List

GlaxoSmithKline adds 2 execs to board

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


GlaxoSmithKline adds 2 execs to board

GlaxoSmithKline PLC named CEO Designate Emma Walmsley and President of R&D Patrick Vallance to the board as executive directors, effective Jan. 1, 2017.

Stacey Cartwright will step down from the board, effective Dec. 31. She leaves after serving for almost 6 years as a nonexecutive director.

In addition, Andrew Witty and Moncef Slaoui will step down from the board March 31, 2017. Slaoui will serve as adviser to the company and the board from April 1, 2017, until his retirement June 30, 2017.